Tango Therapeutics, Inc. - 8-K Filing
Tango Therapeutics reports Q3 2026 net loss of $68.4 million and maintains cash position of $977.5 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $TNGX
Read the full article at SEC EDGAR
Part of the story Definium Therapeutics Reports Positive Phase 3 Clinical Results and Strong Cash Position for Q3 2026 (11 articles)